Get the Stockscreener App
7.83
0.13%
0.010
After Hours:
7.84
0.010
+0.13%
Kamada Ltd stock is traded at $7.83, with a volume of 72,237.
It is up +0.13% in the last 24 hours and down -6.34% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.82
Open:
$7.86
24h Volume:
72,237
Relative Volume:
1.17
Market Cap:
$451.68M
Revenue:
$180.46M
Net Income/Loss:
$20.20M
P/E Ratio:
22.58
EPS:
0.3468
Net Cash Flow:
$16.59M
1W Performance:
+1.56%
1M Performance:
-6.34%
6M Performance:
+16.00%
1Y Performance:
+16.17%
1-Day Range:
$7.72
$7.89
1-Week Range:
$7.55
$7.94
52-Week Range:
$6.50
$9.35
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.83 | 451.10M | 180.46M | 20.20M | 16.59M | 0.3468 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Kamada Q1 earnings call highlights - MSN
KMDA News | KAMADA LTD (NASDAQ:KMDA) - ChartMill
Kamada Ltd Earnings Call Balances Growth And Risks - TipRanks
Benchmark reiterates Kamada stock Buy rating after Q1 miss By Investing.com - Investing.com South Africa
Benchmark reiterates Kamada stock Buy rating after Q1 miss - Investing.com
KMDA Kamada shares rise 351 on strong 121 revenue growth despite EPS missEvent Driven - Newser
Kamada Ltd stock (IL0010952647): biotech shares in focus after recent quarterly update - AD HOC NEWS
Kamada Ltd stock (IL0010952647): plasma?derived therapies under the spotlight after recent updates - AD HOC NEWS
H.C. Wainwright reiterates Kamada stock rating on guidance outlook - Investing.com UK
Kamada Ltd. (NASDAQ:KMDA) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Kamada stock rating on guidance outlook By Investing.com - Investing.com Australia
Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Gr - GuruFocus
Kamada Ltd.Ordinary Shares (NQ: KMDA - FinancialContent
Kamada Falls Short on Q1 2026: $0.07 EPS vs $0.12 Expected - AlphaStreet
Kamada reports Q1 EPS 7c, consensus 12c - TipRanks
Kamada Q1 Earnings Call Highlights - sharewise.com
Kamada Q1 2026 Earnings Call Transcript - MarketBeat
Kamada Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Kamada Reaffirms 2026 Financial Targets After Q1 Results - HarianBasis.co
Kamada (KMDA) Maintains 2026 Financial Projections - GuruFocus
Kamada Down Over 9%, on Pace for Largest Percent Decrease Since October 2022 -- Data Talk - Moomoo
Kamada (KMDA) Reports Strong Q1 Revenue Growth - GuruFocus
Kamada Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Kamada Q1 2026 misses forecasts, stock drops - Investing.com
Kamada Releases Q1 2026 Financial Results - AlphaStreet
Kamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: Kamada Q1 2026 misses forecasts, stock drops By Investing.com - Investing.com Nigeria
Kamada Reports First Quarter Financial Results and Sustains 2026 Goals - HarianBasis.co
Kamada Q1 2026 Earnings Call: Complete Transcript - Benzinga
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Kamada Posts Solid Q1 2026 Results and Reaffirms Full-Year Guidance as Plasma Expansion Advances - TipRanks
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year - The Manila Times
Kamada: Q1 Earnings Snapshot - 10TV
Kamada (NASDAQ: KMDA) posts Q1 2026 results and keeps strong 2026 growth guidance - Stock Titan
Kamada Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Press Release: Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year - Moomoo
Kamada Ltd stock (IL0010952647): Q1 revenue outlook signals 5.6% growth - AD HOC NEWS
Kamada Q1 2026 earnings preview - MSN
Kamada Ltd expected to post earnings of 12 cents a shareEarnings Preview - TradingView
KMDA (Kamada) shares rise 3.51% on strong 12.1% revenue growth despite EPS miss.Community Breakout Alerts - Newser
Stay Ahead of the Game With Kamada (KMDA) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Kamada Ltd. (KMDA) Stock Analysis: Unveiling a 57% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
KMDA Insider Transactions: Officers Sell Stock Options May 2026 - Meyka
Kamada to Report First-Quarter 2026 Results on May 13 - TipRanks
Kamada will post quarterly results before markets open on May 13 - Stock Titan
Kamada (NASDAQ: KMDA) sets May 13 call on Q1 2026 results - Stock Titan
KMDA Insider Transactions: Officers Sell Stock Options April 2026 - Meyka
KMDA SEC FilingsKamada Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - openPR.com
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):